Spontaneous inhibitors of factor VIII (FVIII) are pathogenic IgG autoantibodies of restricted isotypic heterogeneity found in the plasma ofpatients presenting with bleeding episodes and low levels of FVM. We now report the presence of a natural FVIII-neuralizing activity in 85 of500 plasma samples (17%) from healthy donors. FVIII-inhibitory activity was present in F(ab')2 fragments of purified IgG and was dosedependent. The titer of anti-FVIII antibodies in normal plasma ranged between 0.4 (threshold of detection) and 2.0 Bethesda units. Anti-FVIII IgG was also detected in normal plasma by using an ELISA. Anti-FVIH antibodies from healthy individuals did not exhibit restricted isotypic heterogeneity. Mean levels of FVIII activity did not differ significantly between individuals with and without detectable anti-FVIU antibodies in plasma. Natural anti-FVIII IgG inhibited FV1I activity in pools of normal plasma and in plasma of certain donors in the pool but did not inhibit FVII activity in autologous plasma. These observations demonstrate that polyclonal IgG antibodies against procoagulant FVHI are present in healthy individuals. The antibodies are natural IgG autoantibodies and/or antibodies directed against epitopes associated with a so far unidentified allotypic polymorphism of the human FVIII molecule.
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The presence of autoantibodies to factor VIII (FVIII) has so far exclusively been investigated in the plasma of patients with spontaneously occurring severe bleeding episodes in whom circulating autoantibodies are associated with low levels of FVIII. The inhibitors are IgG autoantibodies of restricted isotypic heterogeneity (1) that bind to selective sites on the FVIII molecule, resulting in inhibition of FVIII procoagulant activity (2) (3) (4) .
Natural IgM and IgG autoantibodies reacting with a wide array of serum proteins and hormones, and nuclear and cellular antigens are found in normal human serum (5) . In the present study, we found that the plasma of 17% of 500 healthy blood donors contained FVIII-neutralizing activity. Anti-FVIII activity was present in F(ab')2 fragments from the IgG fraction of the plasma samples with inhibitor activity. FVIIIneutralizing activity of anti-FVIII IgG from a given donor differed with the individual source of FVIII used in the neutralization assay. FVIII Assays. FVIII activity was measured in a one-stage assay by a manual activated partial thromboplastin reagent (APTT) method using human plasma depleted of FVIII (containing <1% FVIII and normal levels of factor V; coagulation time in APTT, >200 sec) (General Diagnostics, Morris Plains, NJ) as substrate and human brain partial thromboplastin and Kaolin (5 mg/ml) as activators. The clotting time of four serial dilutions (1:20 to 1:160) of a reference plasma pool was compared to the clotting time of the same dilutions of each plasma sample. Each plasma sample was tested in duplicate. Dilutions were carried out in barbitalbuffered saline (BBS). The reference plasma pool was prepared with plasma from 20 healthy individuals and calibrated with a standard of FVIII (obtained from T. W. Barrowcliffe, National Institute for Biological Standards, London, U.K.). All assays were performed by the same experienced investigator. Interassay variations ranged between 1 and 2.5% as calculated from five assays performed on the same plasma on 10 occasions. von Willebrand activity was measured using a standard ristocetin cofactor assay.
Quantitation of Anti-FVIII Activity. FVIII-neutralizing activity was measured using the method of Kasper et al. (6) In8hibitor 'iter (BU) [3 Eighty-five of the 500 plasma samples obtained from healthy blood donors (17%) contained detectable FVIII-neutralizing activity of :0.4 BU. Anti-FVIII activity was between 0.4 and 2.0 BU. The same sample with inhibitor activity was reproducibly positive (up to 3 months of storage at 200C). The frequency distribution of plasma samples containing FVIIIneutralizing activity as a function of anti-FVIII activity is shown in Fig. 1 . Fig. 1 Proc. Natl. Acad. Sci. USA 89 (1992) t 4 .3C. activity was also found in F(ab')2 fragments of IgG. Thus, the inhibitory activity to FVIII that may be found in plasma from healthy individuals represents a specific antibody activity that belongs at least to antibodies of the IgG class.
The presence of IgG against FVIII in plasma of healthy donors was also shown by an ELISA with highly purified FVIII. The ELISA discriminated between normal plasmas with no detectable anti-FVIII activity and plasmas containing 015 0 l q , 010. 00s. (Fig. 3) . For positive samples, no correlation was found between the titer of anti-FVIII antibodies in plasma measured by a functional assay and the amount of anti-FVIII antibodies determined by ELISA (Fig. 3) . Anti-FVIII autoantibodies from healthy individuals detected by ELISA belonged to the four sub- classes of IgG whereas antibodies of patients with anti-FVIII autoimmune disease belonged to the IgG1 and IgG4 classes (Fig. 4) . The specificity of the ELISA for FVIII was demonstrated by the following experiment: treated plasma was diluted either in PBS containing 1.0% HSA or in PBS containing 1.0o HSA and FVIII at 60 units/ml. After incubation overnight at 4°C, an ELISA was performed. Incubation of treated plasma with FVIII inhibited the binding of IgG to FVIII-coated plates (Fig. 5) .
Western blot analysis demonstrated that IgG from healthy donors with anti-FVIII activity in plasma recognized predominantly three bands of highly purified FVIII with molecular masses between 210 and 110 kDa and, to a lesser extent, the bands at 94, 80, and 72 kDa (Fig. 6) Proc. Natl. Acad. Sci. USA 89 (1992) Purified IgG from 5 healthy donors (A-E) with anti-FVIII antibodies was incubated with a pool of plasma from 17 healthy individuals without detectable inhibitor to FVIII and with each of the 17 plasma samples constitutive of the pool. Residual FVIII activity was then assessed and expressed as anti-FVIII activity of the IgG. Concentration of IgG from donors A-E that was incubated with a fixed volume of the plasma pool and of plasmas from individual donors 1 to 17 was as follows: A, 141 nmol/ml; B, 115 nmol/ml; C, 91 nmol/ml; D, 44 nmol/ml; E, 31 nmol/ml. -, Below the threshold of detection (i.e., <0.4 BU). levels of FVIII ranged between 60 and 250 units/dl (mean ± SEM = 107 + 19 units/dl) in 14 males with anti-FVIII antibodies and between 85 and 130 units/dl (125 ± 47 units/dl) in 14 males without inhibitor (not significant).
Levels of FVIII ranged from 30 to 175 units/dl (95 ± 28 units/dl) in females with anti-FVIII antibodies and from 60 to 200 units/dl (109 ± 34 units/dl) in females without inhibitor (not significant). Four healthy females with FVIII inhibitor had FVIII levels below 50 units/dl. Levels of von Willebrand activity in plasma of two of these four female donors in whom it could be measured were 66% and 116%. Purified IgG from five healthy individuals with anti-FVIII antibodies was tested for its ability to neutralize FVIII activity in the plasma of 17 normal donors with no detectable anti-FVIII antibodies after a 2-h incubation at 370C. The amount of plasma was adjusted in each assay so that the same amount of FVIII activity was added to the IgG that was tested. IgG from the five healthy individuals with anti-FVIII antibodies neutralized FVIII activity in the plasma from 2 of the 17 donors. It did not neutralize FVIII activity in the plasma from 12 of the 17 donors. IgG from each of the five healthy individuals reacted differently with FVIII in plasma from the three remaining IgG was at 13.6 mg/ml. (Table 2) . In similar experiments, IgG from individuals with anti-FVIII activity did not neutralize FVIII activity in autologous plasma (Table 3) .
DISCUSSION
The present study indicates that IgG antibodies to FVIII may be present in healthy individuals with normal levels of FVIII in plasma. We have screened normal plasmas for the presence of FVIII-neutralizing activity by using heat-treated plasma to inactivate intrinsic FVIII activity. The source of FVIII in the FVIII-neutralization assay was a plasma pool from 20 healthy donors, as recommended (8) . Seventeen percent of 500 regular blood donors were found to exhibit FVIII inhibitory activity in plasma. Purified IgG from plasma with FVIII-neutralizing activity showed dose-dependent inhibitory activity against FVIII. Inhibition of FVIII activity was also found in F(ab')2 fragments from IgG, indicating that FVIII-neutralizing activity is dependent on the antigencombining site of IgG antibodies. A similar proportion among male and female donors displayed anti-FVIII antibodies in plasma. The frequency distribution of plasmas containing FVIII inhibitor as a function of age differed between male and female donors with a tendency to peak among women in age groups with higher frequency of pregnancy. There was a tendency toward an increased frequency of 0 group individuals among donors with natural anti-FVIII antibodies. This observation may be of interest with regard to previous findings of low levels of FVIII in 0 group blood donors (9, 10) .
IgG antibodies to FVIII in donor plasma could also be detected using an ELISA. The ELISA clearly discriminated between positive (>0.4 BU) and negative (<0.4 BU) samples for anti-FVIII activity. For positive samples, the absorbance values determined by ELISA did not correlate with anti-FVIII activity measured in a functional assay. The lack of correlation that was observed between the titers of FVIIIneutralizing activity and the amounts of anti-FVIII IgG determined by ELISA could be due to anti-FVIII antibodies recognizing epitopes located outside the functional sites on the FVIII molecule and/or to the presence of anti-FVIII antibodies of non-IgG isotype. The binding of anti-FVIII antibodies to FVIII was further documented by Western blot analysis.
Natural antibodies of the IgM, IgA, and/or the IgG isotype are found in the plasma of healthy individuals directed against a variety of self-related antigens including idiotypes of anti-FVIII (11, 12) and other autoantibodies (13, 14) . The biological significance of natural autoantibodies is not yet understood although there is evidence that the antibodies may serve immunoregulatory functions, have a role in protein and cell catabolism, and contribute to host defense (5). Natural preimmune autoantibodies in the serum of normal individuals are not associated with clinical signs of disease. Whether autoantibodies that are found in the plasma from patients with autoimmune diseases represent an expansion of naturally occurring autoreactive clones or somatically mutated antigen-driven clones is a matter of debate (15) . The observation of normal FVIII levels in healthy individuals with anti-FVIII antibodies confirms the lack of correlation between the concentration and affinity of autoantibodies and clinical signs of disease. Mean levels of FVIII activity in the plasma of healthy individuals with anti-FVIII antibodies did not differ from the levels measured in individuals with no detectable FVIII-neutralizing activity, suggesting that anti-FVIII antibodies from healthy individuals express no FVIIIneutralizing capacity toward their own FVIII but express an inhibitory activity toward FVIII in the plasma pool that serves to screen for the presence of antibodies. Autologous FVIII was not inhibited by IgG from healthy individuals with FVIII inhibitory activity in plasma whereas the IgG neutralized some but not all allogeneic sources of FVIII. Some ofthe anti-FVIII IgG antibodies found in normal plasma would thus represent antibodies against allogeneic rather than autologous antigenic determinants. The presence of anti-FVIII antibodies may thus provide an explanation for the frequent finding of a low yield of FVIII activity in preparations of a therapeutic cryoprecipitate that contain up to 30% of IgG on a weight basis. Low levels of FVIII that were observed in four healthy females with anti-FVIII antibodies could be due to the following factors: (i) heterozygous von Willebrand disease, as indicated by a ristocetin cofactor activity of 60 units/dl in one of these women; (ii) carriers for hemophilia A; or (iii) alternatively, the autoantibodies found in normal individuals could behave in rare instances in a similar fashion to the autoantibodies that occur in individuals with overt anti-FVIII autoimmune disease.
Thus, anti-FVIII antibodies may be detected in the plasma from almost 20o of healthy individuals. The antibodies may be natural IgG autoantibodies and/or antibodies directed against epitopes associated with a so far unidentified allotypic polymorphism of human FVIII. 
